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1  | INTRODUC TION
A previous version of this article was published in Cancer Science 
(Satouchi et al Cancer Sci 2020;111:4480- 4489)1 and subsequently 
retracted by agreement between the authors and the journal be-
cause the required corrections were too numerous and extensive. 
This article is a revised version of the original article and reflects the 
different tumor response assessment data available at the time of 
this analysis. Progression- free survival and objective response data 
that were originally reported by BICR with a data cut- off date of 15 
February 2019, have been corrected and updated in this article to 
be associated with a data cut- off date of 10 July 2017, because eval-
uation by BICR was discontinued after the second interim analysis 
(per protocol amendment 8). Additionally, PFS data are now reported 
per investigator review with a data cut- off date of 15 February 2019. 
These corrections and updates have been made in the text as well as 
in the figures: the PFS Kaplan- Meier curve has been replaced with 
two curves with data by BICR with a data cut- off date of 10 July 2017 
(Figure 2A) and by investigator review with a data cut- off date of 15 
February 2019 (Figure 2B). Figure 3 has been updated with data by 
investigator review with a data cut- off date of 15 February 2019.
Lung cancer is the leading cause of cancer- related deaths world-
wide2 and represents approximately 20% of all cancer- related deaths 
in Japan.3 Platinum- based chemotherapy has historically been the 
standard first- line treatment for patients with advanced- stage 
NSCLC, particularly those without targetable EGFR or ALK alter-
ations4- 6; however, immunotherapy directed at the PD- 1 checkpoint 
pathway has more recently provided patients with a therapeutic op-
tion that can improve clinical outcomes over standard chemotherapy 
regimens.7 The most recent updates to lung cancer clinical practice 
guidelines in Japan now recommend the anti- PD- 1 immunotherapy 
pembrolizumab as first- line treatment in patients with metastatic 
NSCLC without targetable gene alterations and a PD- L1 TPS of 50% 
or greater.8
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Abstract
This prespecified subanalysis of the global, randomized controlled phase III 
KEYNOTE- 024 study of pembrolizumab vs chemotherapy in previously untreated 
metastatic non- small- cell lung cancer without EGFR/ALK alterations and a pro-
grammed death- ligand 1 (PD- L1) tumor proportion score of 50% or greater evalu-
ated clinical outcomes among patients enrolled in Japan. Treatment consisted of 
pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum- based chemotherapy 
(four to six cycles). The primary end- point was progression- free survival; second-
ary end- points included overall survival and safety. Of 305 patients randomized in 
KEYNOTE- 024 overall, 40 patients were enrolled in Japan (all received treatment: 
pembrolizumab, n = 21; chemotherapy, n = 19). The hazard ratio (HR) for progression- 
free survival by independent central review (data cut- off date, 10 July 2017) was 0.25 
(95% confidence interval [CI], 0.10- 0.64; one- sided, nominal P = .001). The HR for 
overall survival (data cut- off date, 15 February 2019) was 0.39 (95% CI, 0.17- 0.91; 
one- sided, nominal P = .012). Treatment- related adverse events occurred in 21/21 
(100%) pembrolizumab- treated and 18/19 (95%) chemotherapy- treated patients; 
eight patients (38%) and nine patients (47%), respectively, had grade 3- 5 events. 
Immune- mediated adverse events and infusion reactions occurred in 11 patients 
(52%) and four patients (21%), respectively; four patients (19%) and one patient (5%), 
respectively, had grade 3- 5 events. Consistent with results from KEYNOTE- 024 
overall, first- line pembrolizumab improved progression- free survival and overall sur-
vival vs chemotherapy with manageable safety among Japanese patients with meta-
static non- small- cell lung cancer without EGFR/ALK alterations and a PD- L1 tumor 
proportion score of 50% or greater. The trial is registered with ClinicalTrials.gov: 
NCT02142738.
K E Y W O R D S
Japan, non- small- cell lung carcinoma, PD- L1 protein, pembrolizumab, treatment outcome
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Pembrolizumab is a humanized IgG4 mAb that blocks the inter-
action between PD- 1 and its ligands PD- L1 and PD- L2, thereby pro-
moting cytotoxic T cell- mediated antitumor responses.9 The phase I 
KEYNOTE- 001 trial was the first study to show an association be-
tween PD- L1 expression and response to pembrolizumab, showing 
a higher response rate among patients with advanced NSCLC and a 
PD- L1 TPS of 50% or greater.10 The global phase III KEYNOTE- 024 
study subsequently found that patients with previously untreated 
metastatic NSCLC without EGFR mutations or ALK translocations 
and a PD- L1 TPS of 50% or greater had significantly longer OS (HR, 
0.60; 95% CI, 0.41- 0.89; P =.005) and favorable safety outcomes 
with pembrolizumab vs platinum- based chemotherapy.11 A recent 
updated analysis from KEYNOTE- 024 showed that pembrolizumab 
continued to prolong OS compared with chemotherapy with longer 
follow- up (HR for OS, 0.63; 95% CI, 0.47- 0.86; nominal P =.002), 
despite an increase in the number of patients who crossed over 
from chemotherapy to pembrolizumab (82 patients vs 66 patients 
who crossed over to pembrolizumab on study in the previous 
analysis).12
Previous analyses from registry data and clinical trials of an-
ticancer therapies for NSCLC suggest that Asian patients might 
have better survival outcomes than non- Asian patients.13,14 Here 
we report results from patients enrolled in the KEYNOTE- 024 
study in Japan.11
2  | MATERIAL S AND METHODS
2.1 | Patients
Eligibility criteria for enrollment in the KEYNOTE- 024 study 
have been previously published11; this subanalysis included pa-
tients enrolled in KEYNOTE- 024 from 23 sites in Japan. In short, 
adult patients aged 18 years or older were eligible if they had 
previously untreated stage IV NSCLC without activating EGFR 
mutations or ALK translocations, a PD- L1 TPS of 50% or higher, 
measurable disease based on RECIST version 1.1, and an ECOG 
performance status of 0 or 1. For evaluation of PD- L1 status, 
patients must have provided a tumor tissue sample obtained at 
the time of or after diagnosis of metastatic disease and before 
any adjuvant or neoadjuvant therapy. Patients were ineligible if 
they had untreated brain metastases, active autoimmune disease 
that required systemic treatment, had received systemic steroid 
therapy within 3 days before the first dose of study medication or 
were receiving any other immunosuppressive medication, or had 
interstitial lung disease or a history of pneumonitis that required 
steroid treatment.
All patients provided written informed consent before enroll-
ment. The trial protocol and all amendments were approved by an 
institutional review board or independent ethics committee at each 
study site, and the trial was carried out in accordance with Good 
Clinical Practice guidelines and the Declaration of Helsinki.
2.2 | Study design
This was a prespecified subanalysis of the phase III, open- label, 
randomized KEYNOTE- 024 study (ClinicalTrials.gov identifier, 
NCT02142738). As described previously,11 patients were randomly 
assigned in a 1:1 ratio to receive either pembrolizumab 200 mg i.v. 
every 3 weeks for up to 35 cycles or the investigator’s choice of 
one of the following five platinum- based chemotherapy regimens, 
selected before randomization, for four to six cycles: carboplatin 
or cisplatin plus pemetrexed, carboplatin or cisplatin plus gem-
citabine, or carboplatin plus paclitaxel. Pemetrexed- containing 
regimens were permitted only for patients with nonsquamous 
tumors, and pemetrexed maintenance therapy could continue 
after the combination chemotherapy regimen was completed. 
Randomization was stratified by ECOG performance status (0 vs 
1) and tumor histology (squamous vs nonsquamous). Treatment 
continued for the prespecified number of cycles or until radiologic 
disease progression per RECIST version 1.1 by investigator review, 
unacceptable toxicity, concurrent illness precluding further treat-
ment, or a decision was made by the patient or the investigator 
to withdraw treatment. Crossover from chemotherapy to pem-
brolizumab was permitted for patients with documented disease 
progression (per RECIST version 1.1 by BICR) who met safety 
criteria. Patients in either treatment arm who were considered to 
be deriving clinical benefit and were clinically stable (ie, no signs 
or symptoms of clinically significant disease progression, no rapid 
disease progression or progressive tumor requiring urgent alterna-
tive treatment, and no decline in ECOG performance status) could 
continue to receive treatment after disease progression. Patients 
in the pembrolizumab arm who achieved a complete response 
could discontinue treatment if they had been treated for 6 months 
or more and had received at least two treatments beyond the ini-
tial date of complete response.11 Patients who stopped pembroli-
zumab after a complete response or after completing 2 years (35 
cycles) of pembrolizumab and subsequently had disease progres-
sion could receive a second course of pembrolizumab for up to 
17 cycles if they had received no other anticancer therapy since 
the last pembrolizumab dose and continued to meet the required 
eligibility criteria.
2.3 | Endpoints
The end- points in this preplanned subgroup analysis of patients en-
rolled in KEYNOTE- 024 in Japan were the same as for the overall 
study. The primary end- point in the KEYNOTE- 024 study was PFS, 
defined as the time from randomization to the first of either doc-
umented disease progression (per RECIST version 1.1 by BICR) or 
death from any cause. Evaluation by BICR was discontinued after 
the second interim analysis (protocol amendment 8); therefore, 
PFS is reported by BICR with a data cut- off date of 10 July 2017, 
and additionally by investigator review with a data cut- off date of 
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15 February 2019. Secondary end- points were OS (defined as the 
time from randomization to death from any cause), ORR (defined 
as the proportion of patients with a confirmed complete or partial 
response), and safety. Objective response data are reported per 
RECIST version 1.1 by investigator review with a data cut- off date 
of 15 February 2019. Duration of response was an exploratory end- 
point, and was defined as the time from the first documentation of a 
complete or partial response to disease progression.11
2.4 | Assessments
A central laboratory assessed PD- L1 expression in formalin- fixed 
tumor samples obtained through core- needle or excisional biopsy or 
from tissue resected at the time of or after diagnosis of metastatic 
disease from a site not previously irradiated using the PD- L1 IHC 
22C3 pharmDx assay (Agilent Technologies).15 Computed tomogra-
phy (preferred) or MRI was carried out every 9 weeks, with tumor 
response assessed per RECIST version 1.1 by BICR and by investi-
gator assessment. After the end of treatment, patients were moni-
tored for disease status every 3 months until disease progression, 
initiation of new anticancer therapy, withdrawal of consent, loss to 
follow- up, or death; once imaging assessments were stopped (ie, for 
progressive disease or for starting a new anticancer therapy) sur-
vival follow- up was undertaken approximately every 2 months until 
death or withdrawal of consent. Safety was monitored throughout 
the study and for 30 days or more after treatment discontinuation 
(90 days for serious AEs and AEs of interest). All AEs were graded 
in severity per the NCI’s Common Terminology Criteria for Adverse 
Events version 4.0.
2.5 | Statistical analysis
Statistical methods for this subanalysis of the KEYNOTE- 024 study 
were the same as those of the primary analysis,11 except that only 
those patients enrolled in Japan were included. Efficacy analyses 
included all randomized patients, according to the treatment as-
signed (intention- to- treat population); safety analyses included 
all patients who received at least one dose of treatment, accord-
ing to the treatment received. Both PFS and OS were estimated 
using the Kaplan- Meier method. For the analysis of PFS, patients 
who were alive without disease progression and had not initiated 
new anticancer therapy or who were lost to follow- up were cen-
sored at the time of last tumor assessment. For the analysis of OS, 
patients without documented death were censored at the time of 
last follow- up. Between- group differences in PFS and OS were as-
sessed using a stratified log- rank test. Hazard ratios and associated 
95% CIs were assessed using a stratified Cox proportional hazards 
model with Efron’s method of handling ties. The stratified Miettinen 
and Nurminen method was used to assess treatment differences in 
ORR; patients with missing data were considered nonresponders. 
Stratification factors used for randomization were also applied to 
the analyses. One- sided nominal P values are provided for this su-
banalysis. The data cut- off date for response data by BICR was 10 




Among 305 patients randomized in the overall KEYNOTE- 024 study 
population (pembrolizumab, n = 154; chemotherapy, n = 151),11 
40 patients were randomized at Japanese sites (pembrolizumab, 
n = 21; chemotherapy, n = 19; Figure 1) between November 2014 
and October 2015, all of whom received treatment as assigned. In 
the chemotherapy arm, 10 patients crossed over to pembrolizumab 
on study (53%) and an additional three patients received anti- PD- 1 
treatment outside of crossover, for an effective crossover rate of 
68% in the intention- to- treat population. Of patients initially allo-
cated to pembrolizumab, eight patients (38%) received subsequent 
platinum- based chemotherapy.
Patient demographic and baseline clinical characteristics were 
generally well balanced between the treatment arms (Table 1). Most 
patients had nonsquamous tumors (86% in the pembrolizumab arm 
and 95% in the chemotherapy arm) and were former or current 
smokers (95% and 100%, respectively). Median treatment expo-
sure as of the data cut- off date (15 February 2019) was 13.1 months 
(range, 0.03- 47.6 months) in the pembrolizumab arm and 3.5 months 
(range, 0.03- 11.8 months) in the chemotherapy arm, and the median 
time from randomization to data cut- off was 43.3 months (range, 
40.7- 50.5 months).
3.2 | Efficacy outcomes
As of 10 July 2017 and per BICR, a total of 24 PFS events occurred 
among the 40 patients enrolled in Japan, with only eight of them 
occurring in the pembrolizumab arm. The median PFS was not 
reached (95% CI, 4.2 months– NR) with pembrolizumab and was 
4.1 (95% CI, 2.8- 8.3) months with chemotherapy (HR, 0.25; 95% 
CI, 0.10- 0.64; one- sided, nominal P =.001; Figure 2A). In addition, 
the estimated PFS rate at 1 year was higher in the pembrolizumab 
arm (64% [95% CI, 39%– 81%]) vs the chemotherapy arm (24% 
[95% CI, 7%– 46%]).
At the data cut- off date of 15 February 2019 and per investigator 
review, a total of 35 PFS events occurred among the 40 patients en-
rolled in Japan (pembrolizumab, 16; chemotherapy, 19). The median 
PFS was 14.6 (95% CI, 6.1- 41.6) months with pembrolizumab and 
was 4.1 (95% CI, 2.2- 6.3) months with chemotherapy (HR, 0.22; 95% 
CI, 0.10- 0.49; one- sided, nominal P <.001; Figure 2B). In addition, 
the estimated PFS rate at 1 year was higher in the pembrolizumab 
arm (52% [95% CI, 30%– 71%]) vs the chemotherapy arm (5% [95% 
CI, 0%– 21%]).
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F I G U R E  1   CONSORT flow diagram of recruitment of the Japan subset of patients with previously untreated metastatic non- small- cell 
lung cancer in the KEYNOTE- 024 study of pembrolizumab vs chemotherapy. aThe remaining patients did not meet study eligibility criteria 
(n = 14). bIncludes 10 patients who crossed over to pembrolizumab treatment during the study. cIncludes clinical progression. PD- L1, 






21 Allocated to pembrolizumab
21 Received assigned treatment
19 Allocated to chemotherapy
19 Received assigned treatment
7 Carboplatin plus pemetrexed 
(4 had pemetrexed maintenance)
10 Cisplatin plus pemetrexed
(2 had pemetrexed maintenance)
2 Carboplatin plus paclitaxel
186 Patients with samples for PD-L1 evaluation
202 Patients screened in Japan
54 Patients with PD-L1 TPS ≥50%
118 PD-L1 TPS <50%







    9 Progressive diseasec
5 Adverse event
7 Completed
TA B L E  1   Demographic and baseline clinical characteristics of Japanese patients enrolled in the KEYNOTE- 024 study subset
Characteristic
Pembrolizumab (n = 21) Chemotherapy (n = 19)
n (%)a n (%)a
Age (y)
Median 66 67
Range 40- 80 53- 77
Male sex 16 (76) 18 (95)
ECOG performance status
0 7 (33) 8 (42)
1 14 (67) 11 (58)
Smoking status
Former/current 20 (95) 19 (100)
Never 1 (5) 0 (0)
Histology
Squamous 3 (14) 1 (5)
Nonsquamous 18 (86) 18 (95)
Brain metastases 1 (5) 1 (5)
Prior neoadjuvant therapy 0 (0) 0 (0)
Prior adjuvant therapy 0 (0) 0 (0)
aData are n (%), unless otherwise noted.
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As of 15 February 2019, approximately half of the patients had 
died (pembrolizumab arm, n = 9; chemotherapy arm, n = 14). Overall 
survival was longer with pembrolizumab than with chemotherapy. 
Median OS was not reached in the pembrolizumab arm (22.9– NR) and 
was 21.5 months (95% CI, 5.2- 35.0) in the chemotherapy arm (HR for 
OS, 0.39; 95% CI, 0.17- 0.91; one- sided, nominal P =.012; Figure 2C). 
The estimated OS rates in the pembrolizumab arm vs the chemother-
apy arm were 86% (95% CI, 62%- 95%) vs 63% (95% CI, 38%- 80%) at 
1 year, 71% (95% CI, 47%- 86%) vs 37% (95% CI, 17%- 58%) at 2 years, 
and 67% (95% CI, 43%- 83%) vs 26% (95% CI, 10%- 47%) at 3 years.
The ORR by investigator review (data cut- off date, 15 February 
2019) was 67% (95% CI, 43%- 85%) in the pembrolizumab arm and 
32% (95% CI, 13%- 57%) in the chemotherapy arm (one- sided, nom-
inal P =.014). The median duration of response was 29.1 (range, 
4.2- 39.5) months in the pembrolizumab arm and 6.4 (range, 3.1- 
10.4) months in the chemotherapy arm. Among patients in the pem-
brolizumab arm who had a response (n = 14; all partial responses), 
seven patients had completed 35 cycles (2 years) of treatment at 
the time of data cut- off (Figure 3). Of these seven patients, three re-
ceived a second course of pembrolizumab (one completed 17 cycles 
and two discontinued due to PD; all three remained alive at the data 
cut- off of 15 February 2019).
3.3 | Safety
Treatment- related AEs of any grade occurred in all 21 patients 
treated with pembrolizumab and 18 of the 19 patients (95%) treated 
with chemotherapy in this Japanese cohort (Table 2). The most com-
mon treatment- related AEs in the pembrolizumab arm were pyrexia 
(n = 5), diarrhea (n = 4), and rash (n = 4), and the most common in the 
chemotherapy arm were decreased appetite (n = 12), nausea (n = 11), 
and anemia (n = 9). Treatment- related AEs of grade 3- 5 occurred in 
eight patients (38%) in the pembrolizumab arm and nine patients 
F I G U R E  2   Kaplan- Meier estimates of (A) progression- free survival (PFS) per RECIST version 1.1 per independent central review (data 
cut- off date, 10 July 2017), (B) PFS per RECIST version 1.1 per investigator review (data cut- off date, 15 February 2019), and (C) overall 
survival (OS) in the subset of patients with previously untreated metastatic non- small- cell lung cancer in the KEYNOTE- 024 study of 









Pembrolizumab 8/21 (38) NR (4.2−NR) 0.25 (0.10−0.64)
Chemotherapy 16/19 (84) 4.1 (2.8−8.3)



































21 16 14 13 11 5 3 1 0
19 14
0 3 6 9









Pembrolizumab 16/21 (76) 14.6 (6.1−41.6) 0.22 (0.10−0.49)
Chemotherapy 19/19 (100) 4.1 (2.2−6.3)









































8 7 7 6
0 0 0 0
9 8 7 6
0 0 0 0
(B)






























Pembrolizumab 9/21 (43) Not Reached (22.9-NR) 0.39 (0.17-0.91)
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(47%) in the chemotherapy arm. Four patients (19%) in the pembroli-
zumab arm and one patient (5%) in the chemotherapy arm discontin-
ued treatment because of treatment- related AEs. No patient in the 
pembrolizumab arm and one patient (5%) in the chemotherapy arm 
died due to a treatment- related AE. Immune- mediated AEs and infu-
sion reactions of any grade, and regardless of relationship to treat-
ment as assessed by the investigator, occurred in 11 patients (52%) in 
the pembrolizumab arm and in four patients (21%) in the chemother-
apy arm (Table 2). The most common events in the pembrolizumab 
arm (occurring in at least 10% of patients) were infusion reactions 
(n = 4; 19%), and pneumonitis and hypothyroidism (each n = 3; 14%). 
Grade 3- 5 immune- mediated AEs occurred in four patients (19%) in 
the pembrolizumab arm (grade 3 hepatitis, severe skin reaction, and 
uveitis, and grade 4 pneumonitis, all in one patient each) and one pa-
tient (5%) in the chemotherapy arm (grade 3 pneumonitis).
4  | DISCUSSION
This prespecified subanalysis of KEYNOTE- 024 showed that pem-
brolizumab prolonged PFS over platinum- based chemotherapy (HR 
for disease progression or death: by BICR, 0.25 [one- sided, nominal 
P =.001]; by investigator review, 0.22 [one- sided, nominal P <.001]) 
among patients enrolled in Japan with previously untreated meta-
static NSCLC without targetable EGFR/ALK alterations and a PD- 
L1 TPS of 50% or greater. In addition, pembrolizumab prolonged 
OS over chemotherapy (HR for death, 0.39; one- sided, nominal 
P =.012). With few OS events occurring in the pembrolizumab arm, 
median OS was not reached. Treatment with pembrolizumab was as-
sociated with a higher ORR compared with chemotherapy (67% vs 
32%). In addition, pembrolizumab had a manageable safety profile, 
and no new safety signals were identified in this subset of Japanese 
patients relative to previous studies evaluating pembrolizumab mon-
otherapy in patients with advanced NSCLC.10,11,16
The favorable efficacy observed with pembrolizumab in this 
subanalysis among patients in KEYNOTE- 024 enrolled in Japan is 
consistent with the significantly longer PFS (HR, 0.50; P <.001) and 
OS (HR, 0.60; P =.005) observed with pembrolizumab vs chemother-
apy in the overall study population,10,11,16 with somewhat lower HRs 
for PFS (0.25 by BICR; 0.22 by investigator review) and OS (0.39) 
in the current analysis. Although the reason for these lower HRs is 
uncertain, several factors may have contributed, including potential 
F I G U R E  3   Duration of treatment and time to response among patients in the pembrolizumab arm of the KEYNOTE- 024 study with 
an objective response (ie, complete response or partial response [PR]) per RECIST version 1.1 by investigator review (data cut- off, date 15 
February 2019). Bar lengths indicate duration of treatment (first course, dark green; second course, medium green) and months of follow- up 
(light green). Tumor response (ie, PR, stable disease [SD], and progressive disease [PD]) is expressed per RECIST version 1.1 by investigator 
review only. AE, adverse event; PD– L1, programmed death- ligand 1; TPS, tumor proportion score
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differences in baseline characteristics, patient care practices in 
Japan, or in treatment responses between Japanese and non- Asian 
populations.14,17 The smaller number of patients in this subgroup 
analysis and few PFS (by BICR) and OS events in either treatment 
arm could have also contributed. Notably, the positive results from 
the current analysis are consistent with the positive findings in the 
large, multicenter, randomized controlled phase III KEYNOTE- 042 
study as well.18 Similar to results from the overall KEYNOTE- 024 
study noted above, KEYNOTE- 042 showed an OS benefit with 
pembrolizumab vs platinum- based chemotherapy in patients with 
previously untreated locally advanced or metastatic NSCLC without 
EGFR or ALK alterations and a PD- L1 TPS of 50% or greater (HR, 
TA B L E  2   Summary of adverse events (AEs) among patients from Japan in the as- treated population of the KEYNOTE- 024 studya
Treatment- related AEsb
Pembrolizumab (n = 21) Chemotherapy (n = 19)
n (%) n (%)
Any grade 21 (100) 18 (95)
Grade 3- 5 8 (38) 9 (47)
Led to discontinuationc 4 (19) 1 (5)
Led to death 0 (0) 1 (5)
Treatment- related AEsb occurring in ≥15% of 
patients in either arm
Any grade Grade 3- 5 Any grade Grade 3- 5
n (%) n (%) n (%) n (%)
Pyrexia 5 (24) 0 (0) 2 (11) 0 (0)
Diarrhea 4 (19) 1 (5) 3 (16) 0 (0)
Rash 4 (19) 0 (0) 0 (0) 0 (0)
Decreased appetite 3 (14) 0 (0) 12 (63) 2 (11)
Anemia 2 (10) 1 (5) 9 (47) 5 (26)
Malaise 2 (10) 0 (0) 8 (42) 0 (0)
Hypoalbuminemia 2 (10) 2 (10) 4 (21) 2 (11)
Hiccups 1 (5) 0 (0) 6 (32) 0 (0)
Constipation 1 (5) 0 (0) 5 (26) 0 (0)
Peripheral sensory neuropathy 1 (5) 0 (0) 3 (16) 0 (0)
Nausea 0 (0) 0 (0) 11 (58) 0 (0)
Platelet count decreased 0 (0) 0 (0) 8 (42) 3 (16)
White blood cell count decreased 0 (0) 0 (0) 8 (42) 1 (5)
Neutrophil count decreased 0 (0) 0 (0) 4 (21) 1 (5)
Immune- mediated AEs and infusion reactionsd n (%) n (%) n (%) n (%)
Any 11 (52) 4 (19) 4 (21) 1 (5)
Infusion reactions 4 (19) 0 (0) 1 (5) 0 (0)
Pneumonitis 3 (14) 1 (5) 1 (5) 1 (5)
Hypothyroidism 3 (14) 0 (0) 2 (11) 0 (0)
Colitis 1 (5) 0 (0) 0 (0) 0 (0)
Hepatitis 1 (5) 1 (5) 0 (0) 0 (0)
Hyperthyroidism 1 (5) 0 (0) 0 (0) 0 (0)
Severe skin reactions 1 (5) 1 (5) 0 (0) 0 (0)
Thyroiditis 1 (5) 0 (0) 0 (0) 0 (0)
Uveitis 1 (5) 1 (5) 0 (0) 0 (0)
Adrenal insufficiency 0 (0) 0 (0) 1 (5) 0 (0)
aThe as- treated population comprised all randomized patients who received at least one dose of study treatment, according to the treatment 
received.
bAEs that were attributed to treatment by the investigator are listed.
cTreatment- related AEs that led to discontinuation were: pneumonitis (n = 2), fatigue (n = 1), and uveitis (n = 1) among four patients in the 
pembrolizumab group; and hypoxia (n = 1) and pulmonary alveolar hemorrhage (resulting in death) in one patient in the chemotherapy group.
dImmune- mediated AEs and infusion reactions are listed irrespective of attribution to study treatment by the investigator.
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0.69; P =.0003); and additionally showed OS benefit in the overall 
population with PD- L1 TPS of 1% or greater (HR, 0.81; P =.0018).18 
Together, these findings provide support for the use of pembroli-
zumab monotherapy as first- line treatment for PD- L1- positive (TPS 
≥1%) advanced NSCLC, which has received regulatory approval in 
Japan.19 Significant OS benefit has also been shown with pembroli-
zumab plus platinum- based chemotherapy vs chemotherapy alone in 
patients with previously untreated metastatic NSCLC without EGFR 
or ALK alterations, irrespective of PD- L1 expression, in the phase III 
placebo- controlled studies KEYNOTE- 189 (nonsquamous; HR, 0.49; 
P <.001) and KEYNOTE- 407 (squamous; HR, 0.64; P <.001).20,21
Importantly, the OS benefits with pembrolizumab monotherapy 
over chemotherapy among patients in this subanalysis and in the 
global KEYNOTE- 024 study were observed despite relatively high 
crossover rates (53% in the current analysis and 44% in the primary 
analysis of the global study).11 Moreover, the effective crossover 
rate of 68% in the current analysis (after accounting for patients in 
the chemotherapy arm who received anti- PD- 1/PD- L1 therapy out-
side of on- study crossover) was similar to the effective crossover 
rate in the most recent updated analysis from the KEYNOTE- 024 
global study (65%), which continued to show an OS benefit with 
pembrolizumab (HR, 0.63; P =.002), further supporting the efficacy 
gains with pembrolizumab.12
With a median treatment exposure of 13.1 (range, 0.03- 
47.6) months in this subanalysis compared with 7 (range, 0.03- 
18.7) months) in the primary analysis of the KEYNOTE- 024 study,11 
there were no additional safety concerns identified, supporting 
the tolerability of pembrolizumab in Japanese patients with meta-
static NSCLC. In addition, the immune- mediated AEs and infusion 
reactions that occurred with pembrolizumab among the patients 
included in this subanalysis were consistent with those observed 
in previous clinical trials evaluating pembrolizumab monotherapy 
in advanced NSCLC,10,11,16 with few events of grade 3 or greater— a 
finding that is of particular clinical relevance, as monitoring for these 
events is necessary in practice.
Key limitations of this subanalysis are that no alpha was allo-
cated, and because the data represent a subset of patients from the 
global KEYNOTE- 024 study, the sample size was smaller (40 patients 
of 305 who were randomized in the global study). Accordingly, with 
fewer patients, fewer events of PFS (by BICR) and OS occurred, as 
noted above. However, despite the limited power of this analysis, the 
HRs for these end- points suggested substantial PFS and OS benefits 
with pembrolizumab over chemotherapy. Importantly, these results 
provide support for the efficacy and safety of pembrolizumab in 
Japanese patients with advanced NSCLC.
In conclusion, this subanalysis among patients enrolled in 
KEYNOTE- 024 in Japan demonstrated the efficacy and safety ben-
efits of pembrolizumab vs platinum- based chemotherapy, as also 
observed in the primary analysis. These findings provide further 
support for the use of pembrolizumab monotherapy as first- line 
treatment in patients from Japan with metastatic NSCLC without 
activating EGFR mutations or ALK translocations and a PD- L1 TPS 
of 50% or greater.
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